TobaccoReporter logo

Tag: low-nicotine

  • 22nd Century Reports $4.1M in Revenue as it Focuses on Future

    22nd Century Reports $4.1M in Revenue as it Focuses on Future

    22nd Century Group reported first-quarter 2026 revenue of $4.1 million, with a continued focus on expanding its reduced-nicotine VLN cigarette portfolio and distribution footprint. The company said it is gaining traction with adult smokers, with products now available in more than 2,000 stores across 20 states and targeting over 5,000 retail locations by the end of 2026.

    The company is positioning its proprietary low-nicotine technology as aligned with potential future FDA standards, while pursuing a broader product pipeline across cigarettes, filtered cigars and other formats. Despite ongoing net losses, 22nd Century said it is prioritizing distribution growth, regulatory engagement, and margin improvement, with plans to expand licensing opportunities and advance multiple PMTA submissions to support long-term growth.

  • Cabbacis Releases 2025 Financials, Eyes 2027 PMTA Application

    Cabbacis Releases 2025 Financials, Eyes 2027 PMTA Application

    Cabbacis reported continued progress on its iBLEND cigarette platform as part of its 2025 annual filing, highlighting ongoing product development and regulatory preparation. The company, which generated no revenue in 2025 and reported a net loss of $1.58 million, is advancing clinical and consumer research to support a planned Premarket Tobacco Product Application (PMTA) submission to the FDA by January 2027.

    Recent studies cited by the company indicate that iBLEND cigarettes—made with very-low-nicotine tobacco and non-intoxicating hemp—reduced cravings and were rated favorably by adult smokers in sensory testing compared to both traditional and other reduced-nicotine products. Cabbacis plans to launch additional real-world usage studies in 2026, while also strengthening its intellectual property portfolio and pursuing a Regulation A capital raise of up to $7.5 million to fund commercialization and regulatory efforts.